Efficacy and Safety Data from Solid Biosciences’ Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 M...
February 24 2021 - 4:24PM
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company
focused on advancing meaningful therapies for Duchenne muscular
dystrophy (Duchenne), announced that one-year efficacy and safety
data from the ongoing IGNITE-DMD Phase I/II study of SGT-001
microdystrophin gene therapy in patients with Duchenne muscular
dystrophy (Duchenne) will be presented at the 2021 MDA Virtual
Clinical & Scientific Conference. Barry Byrne, MD, PhD,
Associate Chair of Pediatrics and Director of the Powell Gene
Therapy Center at the University of Florida, and IGNITE DMD
principal investigator, will present the data during a virtual oral
session on Thursday, March 18, 2021 at 4 PM ET.
Details of the MDA
presentation:
Session Title: IGNITE-DMD: Phase I/II Ascending
Dose Study of Single IV Infusion of SGT-001 Microdystrophin Gene
Therapy for DMD: One Year Efficacy and Safety Results
Session Date: Thursday, March 18, 2021 4 PM
ET
Registration: The public must
be registered to view live-broadcast sessions, on-demand videos,
virtual networking sessions, exhibits and poster sessions.
To register, visit:
https://mdavirtualconference.org/en/registration
Symposium with Key Opinion
LeadersAlso, on March 18, Solid Biosciences will sponsor a
symposium, “Real World Outcome Measures in Duchenne Muscular
Dystrophy: Current and Novel Assessments of Meaningful Patient
Benefit” at 12 PM ET. The symposium will feature:
- Valeria Ricotti, MD, Co-Founder,
Executive Vice-President & Chief Medical Officer at DiNAQOR
AG
- Chad R. Heatwole, MD, MS-CI,
Professor of Neurology, Associate Director of the Center for Health
+ Technology (CHeT) and CHeT Outcomes Division Director at the
University of Rochester Medical Center
- Craig M. McDonald, MD, Professor
and Chair of the Department of Physical Medicine and Rehabilitation
at the University of California, Davis
Registration: The public must
be registered to view live-broadcast sessions, on-demand videos,
virtual networking sessions, exhibits and poster sessions.
Company Conference CallSolid
Biosciences’ management will host a conference call beginning at
4:30 PM ET on Monday, March 15, 2021 to discuss the IGNITE DMD data
that will be presented at the MDA Conference, the Company’s fourth
quarter and full year 2020 financial results and recent business
developments.
A live webcast of the call will be available on
the Company's website at www.solidbio.com under the “News &
Events” tab in the Investor Relations section, or by clicking here.
Participants may also access the call, by dialing 866-763-0341 for
domestic callers or 703-871-3818 for international callers,
referencing conference ID# 1669808.
The archived webcast will be available in the
“News and Events” section of the Company's website.
About Solid BiosciencesSolid
Biosciences is a life sciences company focused on advancing
transformative treatments to improve the lives of patients living
with Duchenne. Disease-focused and founded by a family directly
impacted by Duchenne, our mandate is simple yet comprehensive –
work to address the disease at its core by correcting the
underlying mutation that causes Duchenne with our lead gene therapy
candidate, SGT-001. For more information, please
visit www.solidbio.com.
Investor Contact:David CareyFINN
Partners212-867-1768David.Carey@finnpartners.com
Media Contact:Erich SandovalFINN
Partners917-497-2867Erich.Sandoval@finnpartners.com
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From Sep 2023 to Sep 2024